Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$0.87
EPS est.
$0.67
EPS surprise
+29.27%
1-day move
+0.57%
Exelixis reported a strong earnings per share, exceeding analyst expectations significantly. However, there was no revenue reported, which leaves some uncertainty about the company's performance. The stock reacted positively, increasing by 0.57%, likely driven by the better-than-expected EPS figure.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.87 | $0.76 | +29.27% |
| Revenue | — | $605M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment. Operating in the health care sector, Exelixis plays a crucial role in addressing unmet medical needs in oncology, which is a significant area of focus given the rising incidence of cancer worldwide.
Last quarter
In Q4 2025, Exelixis reported an EPS of $0.94, significantly exceeding estimates. However, the stock experienced a decline of 2.21% the following day, indicating mixed market reactions.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+38.72%
Avg 1-day reaction
-0.60%
Analysts are generally optimistic about Exelixis's upcoming earnings, expecting solid EPS and revenue figures. However, there are concerns about potential market volatility following the results.
Bull case
If Exelixis beats earnings expectations, it could signal strong demand for its products and lead to positive investor sentiment.
Bear case
Conversely, if the company fails to meet expectations, it may raise doubts about its growth prospects and lead to a decline in stock price.
Key metrics to watch
EPS
$0.76Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$605MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Exelixis achieve an EPS of $0.76 or higher?
This figure is crucial as it reflects the company's profitability and can significantly influence investor sentiment.
Q2
What are the revenue expectations for the quarter?
Revenue performance will indicate market demand for Exelixis's products and its growth trajectory.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may be underestimating the potential for Exelixis to exceed EPS expectations due to strong demand for its oncology products.
Supporting evidence
Exelixis has consistently beaten EPS estimates in recent quarters.
The options market is pricing a larger move than historical averages suggest.
Recent trends in oncology treatments indicate a growing market for Exelixis's offerings.
Key risk
If revenue comes in below $583M, it could undermine confidence in the company's growth prospects.
Pre-commit to what would confirm each case.
The market is closely watching Exelixis's ability to meet or exceed earnings expectations, which will be pivotal for its stock performance.
Bull confirmed if
An EPS of $0.80 or higher would confirm strong operational performance and growth potential.
Bear confirmed if
An EPS below $0.69 would raise concerns about the company's profitability and market position.
What the market is pricing for the move.
Implied Move
±7.1%
Historical Avg
±1.3%
The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings release.
Options are pricing ±9.1% while EXEL has averaged ±1.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
31.2%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
106.74%
of float
Insider
1.85%
of float
Holders
989
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
29,075,377 sh · $1.7B
11.73%
-5.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Exelixis beats expectations, history suggests a potential stock increase of around 0.81%, confirming positive market sentiment.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further commentary.
Miss
Should the company miss expectations, history indicates a likely decline of about 1.14%, raising concerns about future growth.
The lines on the call that would change the story.
Farallon Capital Management LLC
13,468,010 sh · $787.1M
5.44%
2.7%
Renaissance Technologies, LLC
13,427,993 sh · $784.7M
5.42%
-2.2%
Vanguard Portfolio Management LLC
12,043,122 sh · $703.8M
4.86%
-0.3%
AQR Capital Management, LLC
11,023,943 sh · $644.2M
4.45%
-15.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.